KRAS and neoplasm: In the CRC102 model (KRAS G12V MT), the AZD0156/irinotecan doublet (P = 0.0203) and AZD0156/irinotecan/5FU triple combination (P = 0.0090) were again associated with a statistically significant reduction in tumor volume when compared to single-agent AZD0156.